Navigation Links
New Phase II study shows first-line promise of lung cancer drug PF-299
Date:10/12/2010

A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO).

Preliminary results from an ongoing Phase-II trial of the drug PF299804 (PF-299) showed that close to 85% of patients whose cancers harbor mutated forms of the EGFR gene have remained progression-free for at least nine months, reported Dr Tony Mok from the Chinese University of Hong Kong.

While some existing drugs reversibly inhibit the cancer-linked receptor HER-1 (also known as EGFR), PF-299 is a 'pan-HER' inhibitor, which irreversibly inhibits several members of the HER family, including EGFR, HER-2 and HER-4.

"We know that PF-299 is a different compound than drugs such as erlotinib and gefitinib, targeting multiple receptors on the HER pathway," Dr Mok said. "We also know from preclinical work that PF-299 inhibits signaling in both wild-type and mutant EGFR, including forms of NSCLC that are resistant to EGFR inhibitors such as erlotinib and gefitinib."

The current trial includes patients with advanced non-small cell lung cancer and no prior systemic treatment for their disease. All were either non-smokers or light smokers, or were known to have EGFR mutations.

So far, 74 of 80 planned patients have enrolled. Of the 41 with known EGFR status, 27 had activating mutations.

Each patient was administered either 30mg or 45mg of PF-299 once daily, and were assessed every 28 days. After 9 months of treatment, 57.1% of patients overall, and 84.7% of those patients with EGFR mutations, remained progression-free, Dr Mok reported. The expected median progression-free survival with standard-of-care chemotherapy in this patient population is approximately six months.

"Even though these data are preliminary and patients are still being f
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
2. New High Purity Immunoglobulin Enters Phase III in Europe and the US
3. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
4. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
5. Askthedoctor.com Makes Medical Information More Accessible to the Public by Completing Phase 1 of US Expansion
6. Intellicate Announces New “Phased Return to Work” (PRtW) Service
7. Southampton scientists begin Phase II patient trial for new asthma treatment
8. Pilot Testing Phase Ends; Expansion Of Sales Force Begins
9. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... Franklin, TN (PRWEB) August 31, 2014 ... continuing education course provides an in-depth analysis ... and treatment of selected shoulder complex conditions. Over ... utilizing case studies, clinical reasoning and problem solving ... algorithm-based examination format for the special tests of ...
(Date:8/31/2014)... 31 August 2014: Drinking tea reduces non-cardiovascular mortality by ... at ESC Congress today by Professor Nicolas Danchin from ... choose between tea or coffee it,s probably better to ... our way of life. Their effects on cardiovascular (CV) ... divergent results. We investigated the effects of coffee and ...
(Date:8/30/2014)... 2014: A new batteryless cardiac pacemaker based on ... was presented at ESC Congress 2014 today by ... not require battery replacement. , Mr Zurbuchen, a ... ARTORG, University of Bern, Switzerland, said: "Batteries are ... they reach a critically low energy level, physicians ...
(Date:8/30/2014)... MN (PRWEB) August 31, 2014 As ... in home renovation, especially spa style bathrooms and in-home ... (NASS) has observed an increase in interest not only ... the history, culture and health benefits of sauna. ... Finnleo , the North American Sauna Society provides a ...
(Date:8/30/2014)... 2014 UWDress.com, a distinguished wedding dress supplier, ... first range of fashionable outfits. Recently, the company has unveiled ... As an autumn special offer, all these brand new products ... , “We are excited to unveil the new and ... high quality products are available at low prices now. The ...
Breaking Medicine News(10 mins):Health News:North American Seminars Master Clinicians Advanced Shoulder Course Receives PT Continuing Education Course Approval in Georgia, Pennsylvania, Massachusetts and Virginia 2Health News:Drinking tea reduces non-CV mortality by 24 percent 2Health News:Drinking tea reduces non-CV mortality by 24 percent 3Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:As Interest in Saunas Increases, the North American Sauna Society Increases Outreach to Provide Education on History, Design, and Culture 2Health News:UWDress.com’s Beautiful Collection Of “Flowy Bridesmaid Dresses” Released 2
... See health and economic data like you,ve never ... statistics guru Hans Rosling will show how ... data. He will also illustrate how the convergence of ... countries into "Western" and "developing" categories an outdated concept.On ...
... Sports Medicine Provider Times Implementation to ... ALLENTOWN, Pa., May 21 Allscripts announced today that ... medicine in Pennsylvania,s Lehigh Valley, has selected the ... (EHR) and Practice Management (PM) ...
... , May 21 For the second year in ... fans to donate blood through the Red Cross by joining ... ) Red Cross Racing is a program designed to ... times they donate. Participants of this program can get points ...
... neuropathy than blood glucose levels, study suggests , , THURSDAY, ... levels of triglyceride fats are at increased risk of ... or damage of nerves that results in numbness, tingling ... researchers say. , A study by U.S. researchers ...
... A new study published online in Nature Immunology ... immunoglobulin (lg) alleles pair up in the nucleus at stages that ... and Igk) loci. Researchers led by Jane A. Skok ... of Medicine and a member of the NYU Cancer Institute, showed ...
... patient care with PDA-using nursing students in clinical ... illness, enlisting video games to improve analytical and ... myth-busting in advanced pain management courses are some ... at the first international Health Professions Education (HPE) ...
Cached Medicine News:Health News:Gapminder's Hans Rosling Brings Poverty, Health Data to Life at Wilson Center 2Health News:Coordinated Health Selects Allscripts Electronic Health Record and Practice Management to Improve Coordination of Patient Care 2Health News:Coordinated Health Selects Allscripts Electronic Health Record and Practice Management to Improve Coordination of Patient Care 3Health News:Coordinated Health Selects Allscripts Electronic Health Record and Practice Management to Improve Coordination of Patient Care 4Health News:Coordinated Health Selects Allscripts Electronic Health Record and Practice Management to Improve Coordination of Patient Care 5Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3Health News:High Blood Fats Tied to Diabetic Nerve Loss 2Health News:NYU School of Medicine pathology researchers solve another mystery in B lymphocyte development 2Health News:Health Professions Education Conference features 'Headspace Theater,' serious gaming, PDAs 2
(Date:8/29/2014)... 29, 2014   Mast Therapeutics, Inc. ... today that Santosh Vetticaden, Chief Medical Officer and ... for personal reasons, in mid-September.  Edwin L. ... Aires Pharmaceuticals, which Mast acquired earlier this year, ... Company,s interim Chief Medical Officer.  Dr. Parsley previously ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... 2014 Does your doctor know what you,re smoking?  ... recommended marijuana to the over 112,000 currently registered patients under ... of the other roughly 20,300+ active physicians listed with the ... it – even though a poll in February 2014 showed ... have tried it. "With marijuana legalization underway, ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... 10, 2011 MAQUET Cardiovascular, a leading provider ... signed a three-year, dual-source contract with Premier Healthcare ... the Premier membership.  The contract includes the CS300 ... 50cc IABP Catheter, SENSATION® 7Fr. IABP Catheter and ...
... PRINCETON, N.J., Oct. 10, 2011 Pharmasset, Inc. (Nasdaq: ... two treatment arms to the ELECTRON trial of PSI-7977, ... chronic hepatitis C (HCV). The rapid and consistent antiviral ... to date provided the rationale for additional exploratory regimens ...
Cached Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps 2MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps 3Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 2Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 3Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: